{"generic":"Yellow Fever Vaccine","drugs":["Yellow Fever Vaccine","Yf-Vax"],"mono":{"0":{"id":"ekmts0","title":"Generic Names","mono":"Yellow Fever Vaccine"},"1":{"id":"ekmts1","title":"Dosing and Indications","sub":{"0":{"id":"ekmts1b4","title":"Adult Dosing","mono":"<ul><li><b>Yellow fever; Prophylaxis:<\/b> 0.5 mL subQ x 1 dose with booster doses at 10-year intervals (CDC guideline)<\/li><li><b>Yellow fever; Prophylaxis:<\/b> 0.5 mL subQ x 1 dose (WHO guideline)<\/li><\/ul>"},"1":{"id":"ekmts1b5","title":"Pediatric Dosing","mono":"<ul><li>use contraindicated in infants younger than 9 months old because of risk of encephalitis; for infants 6 to 8 months old, travel to endemic areas should be avoided or postponed; if travel is unavoidable, the risks of a serious vaccine adverse event should be weighed against the risk of exposure to yellow fever<\/li><li><b>Yellow fever; Prophylaxis:<\/b> (9 months or older) 0.5 mL subQ x 1 dose with booster doses at 10-year intervals (CDC guideline)<\/li><li><b>Yellow fever; Prophylaxis:<\/b> (9 months or older) 0.5 mL subQ x 1 dose (WHO guideline)<\/li><\/ul>"},"3":{"id":"ekmts1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Yellow fever; Prophylaxis<br\/>"}}},"3":{"id":"ekmts3","title":"Contraindications\/Warnings","sub":[{"id":"ekmts3b9","title":"Contraindications","mono":"<ul><li>acute febrile disease; postpone vaccination<\/li><li>acute hypersensitivity to any component of the vaccine, including gelatin, eggs or chicken protein<\/li><li>immunosuppression due to illness (eg, AIDS or other clinical manifestations of HIV, generalized malignancies, lymphoma, leukemia, transplantations, thymus disorders associated with abnormal immune cell function), or current or recent radiation or drug therapy; postpone or avoid vaccination<\/li><li>infants below 9 months of age; risk of encephalitis<\/li><li>lactation; risk of transmission of vaccine components<\/li><li>thymic dysfunction, history of thymoma, thymectomy, myasthenia gravis; increased risk of vaccine-associated viscerotropic disease<\/li><\/ul>"},{"id":"ekmts3b10","title":"Precautions","mono":"<ul><li>adults 60 years of age and older, especially if receiving primary vaccination; increased risk for adverse events including yellow fever vaccine-associated viscerotropic disease and yellow fever vaccine-associated neurologic disease<\/li><li>anaphylaxis may occur without history of exposure<\/li><li>defer blood donations for 2 weeks after receiving vaccine<\/li><li>HIV infection, asymptomatic; seroconversion rate reduced<\/li><li>infants aged 6 months to 8 months; increased risk of yellow fever vaccine-associated neurologic disease<\/li><li>latex allergy, history; vial stopper contains dry, natural latex rubber<\/li><li>neurotropic disease, vaccine-associated; has been reported<\/li><li>pregnancy; seroconversion rate reduced<\/li><li>report adverse events to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or at www.vaers.hhs.gov<\/li><\/ul>"},{"id":"ekmts3b11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B2 (AUS)<\/li><\/ul>"},{"id":"ekmts3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"ekmts4","title":"Drug Interactions","sub":[{"id":"ekmts4b13","title":"Contraindicated","mono":"<ul>Trabectedin (theoretical)<\/ul>"},{"id":"ekmts4b14","title":"Major","mono":"<ul><li>Aclarubicin (established)<\/li><li>Adalimumab (theoretical)<\/li><li>Aldesleukin (established)<\/li><li>Altretamine (established)<\/li><li>Amonafide (established)<\/li><li>Amsacrine (established)<\/li><li>Asparaginase (established)<\/li><li>Azacitidine (established)<\/li><li>Azathioprine (established)<\/li><li>Bleomycin (established)<\/li><li>Broxuridine (established)<\/li><li>Busulfan (established)<\/li><li>Capecitabine (established)<\/li><li>Carboplatin (established)<\/li><li>Carmustine (established)<\/li><li>Certolizumab Pegol (theoretical)<\/li><li>Chlorambucil (established)<\/li><li>Cholera Vaccine (theoretical)<\/li><li>Cisplatin (established)<\/li><li>Cladribine (established)<\/li><li>Cyclophosphamide (established)<\/li><li>Cyclosporine (theoretical)<\/li><li>Cytarabine (established)<\/li><li>Cytarabine Liposome (established)<\/li><li>Dacarbazine (established)<\/li><li>Dactinomycin (established)<\/li><li>Daunorubicin (established)<\/li><li>Daunorubicin Citrate Liposome (established)<\/li><li>Decitabine (established)<\/li><li>Docetaxel (established)<\/li><li>Doxifluridine (established)<\/li><li>Doxorubicin (established)<\/li><li>Doxorubicin Hydrochloride Liposome (established)<\/li><li>Edatrexate (established)<\/li><li>Eflornithine (established)<\/li><li>Epirubicin (established)<\/li><li>Estramustine (established)<\/li><li>Etanercept (established)<\/li><li>Etoposide (established)<\/li><li>Everolimus (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Floxuridine (established)<\/li><li>Fludarabine (established)<\/li><li>Fluorouracil (established)<\/li><li>Fotemustine (established)<\/li><li>Gallium Nitrate (established)<\/li><li>Gemcitabine (established)<\/li><li>Golimumab (theoretical)<\/li><li>Hydroxyurea (established)<\/li><li>Idarubicin (established)<\/li><li>Ifosfamide (established)<\/li><li>Immune Globulin (probable)<\/li><li>Infliximab (theoretical)<\/li><li>Irinotecan (established)<\/li><li>Lomustine (established)<\/li><li>Mechlorethamine (established)<\/li><li>Melphalan (established)<\/li><li>Mercaptopurine (established)<\/li><li>Methotrexate (established)<\/li><li>Mitolactol (established)<\/li><li>Mitomycin (established)<\/li><li>Mitotane (established)<\/li><li>Mitoxantrone (established)<\/li><li>Mycophenolic Acid (theoretical)<\/li><li>Oxaliplatin (established)<\/li><li>Paclitaxel (established)<\/li><li>Pegaspargase (established)<\/li><li>Pentostatin (established)<\/li><li>Pipobroman (established)<\/li><li>Pirarubicin (established)<\/li><li>Plicamycin (established)<\/li><li>Procarbazine (established)<\/li><li>Raltitrexed (established)<\/li><li>Rilonacept (theoretical)<\/li><li>Rituximab (established)<\/li><li>Secukinumab (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sirolimus (probable)<\/li><li>Streptozocin (established)<\/li><li>Tacrolimus (theoretical)<\/li><li>Teceleukin (established)<\/li><li>Tegafur (established)<\/li><li>Temsirolimus (theoretical)<\/li><li>Teniposide (established)<\/li><li>Thioguanine (established)<\/li><li>Thiotepa (established)<\/li><li>Topotecan (established)<\/li><li>Treosulfan (established)<\/li><li>Trimetrexate (established)<\/li><li>Trofosfamide (established)<\/li><li>Uracil Mustard (established)<\/li><li>Ustekinumab (theoretical)<\/li><li>Vinblastine (established)<\/li><li>Vincristine (established)<\/li><li>Vincristine Sulfate Liposome (established)<\/li><li>Vindesine (established)<\/li><li>Vinorelbine (established)<\/li><\/ul>"},{"id":"ekmts4b15","title":"Moderate","mono":"<ul><li>Abatacept (probable)<\/li><li>Leflunomide (established)<\/li><\/ul>"}]},"5":{"id":"ekmts5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Musculoskeletal:<\/b>Myalgia<\/li><li><b>Neurologic:<\/b>Headache<\/li><li><b>Other:<\/b>Fever (Infants, up to 21%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Neurologic:<\/b>Guillain-Barr  syndrome (very rare), Meningoencephalitis, Post yellow fever vaccination encephalitis, Seizure (very rare)<\/li><li><b>Other:<\/b>Multiple organ failure, Yellow fever vaccine-associated viscerotropic disease (YEL-AVD)<\/li><\/ul>"},"6":{"id":"ekmts6","title":"Drug Name Info","sub":{"0":{"id":"ekmts6b17","title":"US Trade Names","mono":"Yf-Vax<br\/>"},"2":{"id":"ekmts6b19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"ekmts6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"ekmts6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"ekmts7","title":"Mechanism Of Action","mono":"Following subcutaneous injection, yellow fever vaccine induces the formation of protective antibodies in susceptible individuals. This provides active immunity against yellow fever infection that probably lasts for more than 10 years .<br\/>"},"9":{"id":"ekmts9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>reconstitute using only the supplied diluent; let set for 1 to 2 minutes then carefully swirl until suspension is uniform<\/li><li>vaccine is slight pink-brown suspension after reconstitution<\/li><li>swirl well before use; do not shake vigorously<\/li><li>reconstituted vials should be used within 1 hour<\/li><li>a 5\/8-inch to 3\/4-inch needle is recommended<\/li><\/ul>"},"11":{"id":"ekmts11","title":"How Supplied","mono":"<b>YF-VAX<\/b><br\/>Subcutaneous Powder for Suspension: 47400000000 PFU<br\/>"},"13":{"id":"ekmts13","title":"Clinical Teaching","mono":"This drug may cause myalgia, headache, and fever. Advise patient that these effects may occur for up to 30 days following vaccination.<br\/>"}}}